Orexigen Therapeutics has reported that the FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 10, 2014 for the companys recent resubmission of the Contrave (naltrexone sustained release (SR)/bupropion SR) NDA. The move indicates that the agency considers the NDA to be a complete response to the FDA’s January 31, 2011 action letter. Orexigen resubmitted the Contrave NDA in December 2013 following the  announcement of the successful interim analysis of Contrave&#821...